Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MPC-SHRC
- Development stage
- Phase 2
- Lead developer
- Mission Pharmacal
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
MPC-SHRC is an investigational oral drug developed for the relief of symptoms associated with uncomplicated urinary tract infections (UTIs) in women. It has been evaluated in a Phase 2, randomized, double-blind, placebo-controlled clinical trial for this indication. The specific mechanism of action and active ingredients have not been publicly disclosed in available sources. The drug is administered as an oral tablet four times daily for three days during the study period. The developer and sponsor of the clinical trial is Mission Pharmacal[6].
- Brand names
- MPC-SHRC
- Other names
- MPC-SHRC
02
Targets
mAChR (Muscarinic acetylcholine receptors)COX
Beyond the preview
Go deeper on MPC-SHRC.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MPC-SHRC.